One year after Vanda, are diagnostics patents transforming into methods of treatment to overcome Mayo-based rejections?-Reference-Cited by-同舟云学术

One year after Vanda, are diagnostics patents transforming into methods of treatment to overcome Mayo-based rejections?

Published:2020-03 Issue:3 Volume:38 Page:279-283
ISSN:1087-0156
Container-title:Nature Biotechnology
language:en
Short-container-title:Nat Biotechnol

Author:

Aboy Mateo,Crespo Cristina,Liddell Kathleen,Davey Neil,Liddicoat Johnathon^ORCID,Minssen Timo^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Biomedical Engineering,Molecular Medicine,Applied Microbiology and Biotechnology,Bioengineering,Biotechnology

Link

http://www.nature.com/articles/s41587-020-0440-4.pdf

Reference15 articles.

1. Mayo Collaborative Services v. Prometheus Laboratories, Inc. in S. Ct. Vol. 132 1289 (Supreme Court, 2012).

2. Aboy, M., Crespo, C., Liddell, K., Minssen, T. & Liddicoat, J. Nat. Biotechnol. 37, 513–518 (2019).

3. Subject Matter Eligibility Examination Guidance, USPTO. https://www.uspto.gov/patent/laws-and-regulations/examination-policy/subject-matter-eligibility (USPTO, 2014–2019).

4. Vanda Pharmaceuticals Inc., v. West-Ward Pharmaceuticals International Ltd. in F.3d Vol. 887 1117 (United States Court of Appeals for the Federal Circuit, 2018).

5. USPTO Memorandum—Recent Subject Matter Eligibility Decision: Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals. https://www.uspto.gov/sites/default/files/documents/memo-vanda-20180607.PDF (2018).

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Diagnostics Patenting After Mayo v. Prometheus: An Empirical Analysis;SSRN Electronic Journal;2023